Our previous analyses have indicated that the AT subtype of HNSCC has two intriguing properties with respect to BET inhibition: first, H3K27ac-marked enhancers unique to the AT subtype regulate genes enriched for known BET inhibitor resistance pathways, and, second, the AT subtype is able to uniquely upregulate genes enriched for BET inhibitor resistance pathways after treatment with BET inhibitor (Figures 2B,C,G; Supplementary Tables S2, S3; Figures 3E,F). The gene discussed is DNER; the disease is head and neck squamous cell carcinoma.